基础医学与临床 ›› 2015, Vol. 35 ›› Issue (1): 65-68.

• 研究论文 • 上一篇    下一篇

塞来昔布抑制人胰腺癌细胞系PANC-1的增殖、侵袭、迁移能力

谷倬宇1,李军1,李思源2,肖智伟3,周婷4   

  1. 1. 新疆石河子大学医学院第一附属医院
    2. 石河子大学医学院
    3. 石河子大学 医学院
    4. 石河子大学医学院第一附属医院中心实验室
  • 收稿日期:2014-08-14 修回日期:2014-10-21 出版日期:2015-01-05 发布日期:2014-12-30
  • 通讯作者: 李军 E-mail:xjlijun@163.com
  • 基金资助:
    新疆生产建设兵团国际合作基金资助项目;新疆研究生科研创新项目

Celecoxib inhibits proliferation, invasion and migration of human pancreatic cancer cell line PANC-1 in vitro

  • Received:2014-08-14 Revised:2014-10-21 Online:2015-01-05 Published:2014-12-30

摘要: 目的 探讨COX-2抑制剂塞来昔布对人胰腺癌细胞系PANC-1增殖、侵袭、迁移能力的影响,确定塞来昔布的最佳作用浓度和最适宜的应用时间。 方法 不同浓度的塞来昔布(20、60和100μmol/L)处理胰腺癌细胞不同时间(24、48和72h)后,用MTT比色法检测细胞的增殖能力;用Transwell实验检测细胞的侵袭能力;采用细胞划痕实验检测细胞的迁移能力。 结果 MTT结果显示塞来昔布作用后胰腺癌细胞的增殖能力下降,呈时间和浓度依赖性(P<0.05);Transwell侵袭实验结果显示塞来昔布作用后胰腺癌细胞的侵袭能力下降,呈浓度依赖性(P<0.01);划痕实验结果显示塞来昔布作用后胰腺癌细胞的迁移能力下降,呈浓度依赖性(P<0.01)。 结论 塞来昔布以浓度梯度、时间梯度的形式减弱人胰腺癌细胞系PANC-1的增殖能力,以浓度梯度的形式减弱人胰腺癌细胞株PANC-1的侵袭及迁移能力。

关键词: 胰腺癌, 塞来昔布, 增殖, 侵袭, 迁移

Abstract: Objective To investigate the effects of cyclooxygenase-2 inhibitor celecoxib on proliferation, invasion and migration of human pancreatic cancer cell line PANC-1 and then determine the optimal concentration of celecoxib and the most suitable application time. Methods Human pancreatic cancer cell line PANC-1 was treated with diverse concentrations of celecoxib (20、60、100μmol/L) for different durations (24、48、72h). Cell proliferation, invasion and migration capabilities were measured by MTT colorimetry, Transwell invasion assay, and scratch assay respectively. Results The proliferation capability of PANC-1 cell was reduced by celecoxib in a concentration- and time-dependent manner (P<0.05). In addition, the invasion and migration capabilities were decreased by celecoxib in a concentration-dependent manner (P<0.01). Conclusions Celecoxib attenuates the proliferation of human pancreatic cancer cell line PANC-1 in a concentration- and time-dependent manner. Celecoxib attenuates the invasion and migration in a concentration-dependent manner.

Key words: Pancreatic cancer, celecoxib, proliferation, invasion, migration